ebook img

American Journal of Kidney Diseases 1999: Vol 34 Index PDF

47 Pages·1999·13.1 MB·English
by  
Save to my drive
Quick download
Download
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.

Preview American Journal of Kidney Diseases 1999: Vol 34 Index

AUTHOR INDEX Chandler, G., $2:40 Dominguez-Cabrera, C., 508 Fukushima, K., 1016 Chang, S.-K., 259 Domrongkitchiaporn, S., 29 Furuta, T., 894 Charra, B., 597 Donadio, J. V., Jr., 549 Chauveau, P., 500 Dong, Y., 583 Gabow, P. A., 120, 639, 4:E17, 863 ChazaJn., A ., 14 Duley, I., 863 Gallo, G., 884 Chew, 'S. T. H., 135 Dunfee, T. P., 222 Gan, B. S., 932 Chiba, S., 894 Dunn, S. R., 818 Garcia, C., 264 Chiu, M. Y., 540 Dydak, U., 875 Garcia, J., 43 Choi, J.-S., 259 Dysseleer, A., 166 Garcia-Buela, J., 824 Chot, Po €. L., 3:-E12 Garg, K., 120 Choi, Y.-J., 5:E22 Ebben, J. P., 1065 Gaughan, W. J., 4:E16 Choudhury, S., 869 Elinder, C.-G., 1083 Geadah, D., 486 Cline, K. N., 713 Elston, O., S2:40 Gelfand, E., 65 Clutterbuck, E., 155 Eltayeb, B. O., 818 Gerakis, A., 521 Coimbra, T. M., 328 Emerson, S., 688 Germino, G. G., 1152 Collins, A. J., 1065 Emoto, M., 832 Ghiggeri, GM., 1048 Combarnous, F., 839 Engels, K., 228 Ghio, L., 1048 Combe, C., 500 Erbas, B., 140 Giacchetti, G., 1002 Comerford, S. A., 180 Ethier, J., 125 Ginevri, F., 1048 Compte, T., 264 Eto, T., 114 Girgis, [., 1105 Connors, A. F., Jr., 706 Everson, S. E., 1065 Gitomer, J. J., 1:E2, 2:E2, 3:E8, Conrad, K. P., 1142 4:E15, 5:E19, 6:E24 Constantini, E. G., 1065 Fainaru, M., 438 Glynne, P., 155 Constantino, T., 1105 Contoreggi, C. S., 207 Faraggiana, T., 85 Godwin, D. A., 651 Farina, M., 618 Goffin, E., 166 Contreras, G., 1105 Cooney, S. K., 918 Fassi, A., 626 Goldsmith, D., 155 Feigin, M., 1129 Goldstein, C. S., 588 Cordido, F., 824 Cosby, R. L., 304 Feinfeld, D. A., 702 Goldstein, S. L., 49 Felsenfeld, A. J., 456 Gomez-Garcia, L., 338 Cosio, F. G., 731 Ferder, L., 445 Gonzalez-Roncero, F., 338 Ferguson, R. M., 731 Goto, M., 845 Cosyns, J.-P., 166 Feriozzi, S., 85 Goumenos, D., 521 Courteau, S., 486 Fernandez-Rodriguez, A. M., 508 Grassi, C., 618 Courvoisier, S., 745 Fervenza, F. C., 549 Grcevska, L., 911 Criswell, L. A., 1040 Crowley, S. T., 161 Fiacco, V., 464 Green, M., 438 Fick-Brosnahan, G., 639, 4:E17 Greer, J. W., S1:1 Cunniff, P. J., 349 Fink, J. C., 1, 694 Grimm, E. M., 1:E2. 2:E2, 3:E8, Curtis, J. J., 756, 869 Finkel, K. W., 1:E2, 2:E2, 3:E8, 4:E15, 5:E19, 6:E24 4:E15, 5:E19, 6:E24 Gruenhagen, S. E., 324 D’ Agati, V. D., 184, 588 Finkelstein, F. O., 752 Gualberti, L., 1105 Daha, M. R., 344 Fioretto, P., 1002 Gude, F., 996 Dall’ Amico, R., 1048 Fischer, F.-P., 678 Guignard, J.-P., 2:E3 Darnell, A., 273 Fishbane, S., $2:47 Guillevin, L., 633 Daskal, I., 5:E21 Fitzwilliam, J., 135 Guindeo-Casastis, M. C., 508 Davis, C. L., 405 Flanders, W. D., 1075 Gulati, S., 646 Davis, J. L., 212 Flores-Suarez, L. F., 364 Giinther, E., 150 Deacon, A., 155 Fogo, A. B., 1:E1, 2:E1, 3:E7, 768, Gupta, A., 646 De Cavanagh, E. M. V., 445 4:E14, 5:E18, 5:liv, 6:E23 Gupta, K. L., 6:E25 Deenitchina, S. $., 279 Foran, M. P., 824 Giirgiin, C., 218 DeFranco, P., 65 Fouque, D., 839 Gutierrez, C., 264 Delawari, E., 839 Fraga, C. G., 445 Delclaux, C., 500 Frankel, W. L., 731 Ha, K.-S., 259 Delmez, J., 493 Frankenfield, D. L., 721, S2:5, 1075 Haag-Weber, M., 247 Depner, T. A., 493 Frederick, P. R., 721, 1075 Haas, M., 69, 540 De Précigout, V., 500 Freedman, B. I., 254 Hakim, R., 471 Deteix, P., 633 Frey, F. J., 569 Halimi, S., 795 Di Cataldo, A. 98 Friedman, E. A., 775 Hamm, L. L., 960 Dickey, K. W., 752 Friedman, G., 65 Hammer, R. E., 180 Djurdjev, O., 125 Frinak, S., 21 Hansen, C., 651 Dolfin, T., 1129 Fujimoto, S., 114 Hanson, J., S1:1 Domico, J., 228 Fujishima, M., 279, 1096 Hao, W., 1065 1162 AUTHOR INDEX Hara, S., 926 Jakob, S., 569 Lafferty, J., 1105 Harchowal, J., $2:40 James, L. R., 932 Lai, F. M.-M., 3:E12 Hassan, M. H., 4:E16 Jeffrey, R., 937 Lai, K.-N., 235, 380, 1056, 6:E26 Hebert, L. A., 308 Jha, V., 6:E25 Lai, L.-W., 378 Hegewisch-Becker, S., 5:E20 Jiménez, A., 43 Lajoie, G., 932 Heidland, A., 433 Jindal, K., 125 Lam, C. C. K., 889 Heimbiirger, O., 947, 1083 Jirakranont, B., 29 Larroche, C., 633 Heinzelmann, M., 384 Johnson, A. M., 120, 639, 4:E17, 863 Lasne, Y., 839 Helgerson, S. D., 1075 Johnson, C. A., 657, $2:5 PaCS. 315 Henry, M. L., 731 Jones, C.A;,'S1:1 Laville, M., 839 Hercz, G., 688 Josephson, M. A., 69, 540 Law, M.-C., 235, 1056 Hermans, C., 166 Joshi, K., 6:E25 Leblanc, M., 486 Herzenberg, A. M., 560 Juillard, L., 838 Lee, H.'S., 1:E3 Hess, J. M., 207 Junaid, S. M. A., 92 Lee, H.-A., 259 Hino, S., 1016 Lee; K.. C., 355 Hirakata, E., 1096 ee, Ss MLK. 565 Kahn, S. [., 14 Hirakata, H., 279, 1096 Lehmann, H., 364 Kaiser, J. W., 21 Hirano, K., 902 Leung, C. B., 514, 3:E12, 1056, 1132 Kaneko, K., 170 Hirano, T., 279 Levey, A. S., 308 Kaplan, B., 65 Hirth, R., S1:1 Levin, A., 125 Kara, N., 140 Hisanaga, S., 114 Levin, N. W., 493 Kasiske, B., 884 Ho; ‘CP. G:E27 Levine, D. Z., 759 Katafuchi, R., 279 Hoen, B., $2:30 Levine, J. S., 3:E11 Katori, H., 926 Holden, J. K., 560 Levinksy, N. G., 775 Katz, O., 146 Holman, D’A., 1033 Lewis, E. J., 308, 809, 818 Katzir, Z., 146, 438 Hong, S.-Y., 259 Lewis, J. B., 308, 768, 809 Kausz, A. T., 651, 688 Horl, W. H., 247, $2:25 Lewis, R. M., 869 Kawahara, H., 170 Hortal-Cascon, L., 508 Ge sisa5 Kawamoto, M., 114 Horvath, F., Jr., 966 Li, F. K., 6:E26 Kawamura, T., 902 Hosoya, T., 902 LasPoK. 12353914, 10562 1132 Kay, A., 405 Hossfeld, D. K., 5:E20 Lien, Y.-H. H., 378 Keane, W. F., 2:xliii Hotta, O., 894 Light, P. D., 694 Kelley, V. R., 761 Houri, C., 1129 Lijima, K., 289 Kew, J., 3:E12 Hovick, E. T., 1089 Lilaj, T., 247 Khajehdehi, P., 92 Hudson, B. G., 549 Lindholm, B., 1083 Khaodhiar, L., $2:35 Hulbert-Shearon, T., S1: Li Volti, S., 98 Ka, PK. T.; 3:B12 Hull, S., 36 Lobo, P. I., 706 Kim, C. W., 1:E3 Hunchik, M., 1125 Locatelli, F., 795 Kam, J.'S., 3:E13 Lépez-Hidalgo, R., 338 Hyndman, M. E., 669 Kim, J. Y., 1:E3 Lui, S. L., 889 Kinoshita, H., 114 Lynn, M. L., 61 Kitamura, K., 114 laina, A., 146 Kiyohara, Y., 279 Ibayashi, S., 1096 Kleiner, M., 1105 Ma, J. Z., 1065 lijima, K., 854 Kobayashi, S., 3:E10 Maaz, D., 14 Ikizler, T. A., 471 Kocak, H., 140 Maccario, M., 530 Imai, H., 902 Kohli, H. S., 6:E25 McClellan, W. M., 721 Imai, T., 926 Kopp, J. B., 177 McCue, P. A., 4:E16 Indridason, O. S., 135 Korbet, S. M., 713 McDonald, J. C., 61 Inoue, S., 926 Korzets, Z., 1129 Macdougall, I. C., 2:40 Inoue, Y., 289, 854 Kosorok, M. R., 657 McGowan, T. A., 818 Inserra, F., 445 Kotaki, S., 170 MacGregor, G. A., 583 Iqbal, A Kotani, M., 845 Macia, M., 43 Isaacs, R. B., 706 Kovacs, B., 5:E21 McMillan, R. W., 61 Ishida, A., 3:E10 Kovalik, E. C., 135 Magil, A. B., 560 Ishida, I., 1096 Kubo, M-a., 1096 Magnusen, H. M., 324 Ismail-Beigi, F., 189 Kuhlmann, U., 678 Mailloux, L. U., 359 Itin, P., 745 Kurnik, B. R. C., 1010 Maioli, M., 1002 Kurth, S. J., 694 Malhotra, D., 304 Jaber, B. L., 349 Kurtzman, N. A., 1137 Manco-Johnson, M., 120 Jacobs, M. G., 65 Kuzuhara, K., 926 Manns, B. J., 669 Jain, A., S1:1 Kwong, Y. L., 889 Manor, Y., 1129 AUTHOR INDEX Mantero, F., 1002 Nakao, K., 845 Perez, G., 1105 Markowitz, G. S., 184, 588 Nanhou, A., 364 Pérez-Borges, P., 508 Marks, E. A., 565 Nass, K., 955 Pérez-Oller, L., 273 Marti, H.-P., 569 Navarro, J. F., 43 Perico, N., 626 Martin, B. R., 324 Navarro, M., 338 Pesavento, T. E., 731 Martin-Herrera, C., 338 Neugarten, J., 884 Peterson, D. D., 1089 Martin-Malo, A., 456 Neumayer, H.-H., 556, 3:E9 Petronis, J. D., 207, 341 Martinez-Vea, A., 264 Newman, N., 464 Pfister, M., 569 Maruyama, K., 1016 Nickeleit, V., 1146 Pierratos, A., 597 Maruyama, N., 902 Niederer, U., 569 Piette, J. C., 633 Matas, Z., 438 Nishio, H., 854 Pirsch, J., 869 Matos, V., 2:E3 Nishiyama, J-i., 3:E10 Pirson, Y., 166 Matsushita, Y., 926 Nishiyama, K., 289, 854 Pittala, D., 98 Matzke, G. R., 203 Nishizawa, Y., 832 Polenakovik, M. H., 911 McClellan, W. M., 1075 Nock, S. L., 706 Pomeranz, A., 1129 McCloughlin, J., 1105 Nosadini, R., 1002 Ponticelli, C., 530, 618 McGinn, T. G., 1105 Nowack, R., 364 Port, F. K., S1:1, 424 Meehan, S. M., 69 Pozzi, C., 618 Mees, E. J. D., 218 Oda, K., 611 Prabhu, P. N., 937 Meier, D., 875 Ogawa, Y., 845 Prajapati, D., 932 Meier-Kriesche, H.-U., 65 Ojo, A. O., S1:1 Pressman, M. R., 1089 Mendelssohn, D., 125 Okada, H., 170 Pugh, J., 721 Mercer-Jones, M. A., 384 Okada, M., 1016 Puhlman, M. E., 918 Messana, J. M., 424 Oliver, J. A., 264 Pupim, L. B., 471 Mettang, T., 678 Omae, T., 1096 Pusey, C., 155 Meyers-Purkiss, A., S1:1 O'Neill, W. C., 955 Meysen, T., 433 Oreopoulos, D. G., 663 Quadri, K., 5 5 Michaux, L., 166 Ornt, D., 493 Quaglini, S., 53 0 Mihatsch, M. J., 745, 1146 Ortner, M.-A., 556 Quan, A., 11 25 Mila, M., 273 Orzol, S., 424 Mir, R., 702 Owen, W., 493 MMiitwtam,a n,M. , N.2,8 91 73 OOzweenn,, SW.,. 1F4.0, Jr., 721, S2:1, §2:5 RRaahgiumsia,, SR..,, 8958 Miyazato, H., 1016 Ozenne, S., 500 Raj, D. S. C., 597 Moberly, J. B., 663 Ozerkan, F., 218 Ram, S. J., 478 Modai, D., 146 Ozkahya, M., 218 Reddy, S. M., 3:E11 Mok, C. C., 315 Regan, F., 207, 341 Molero-Labarta, T., 508 Rehman, S. U., 471 Moll, S., 745, 1146 Padhi, I. D., 222 Reilly, R. F., 161 Pas CYC). 107 Remuzzi, A., 626 Mollica, F., 98 Palmer, R. B., 651 Remuzzi, G., 626, 951 Molony, D. A., 1:E2, 2:E2, 3:E8, 4:E15, 5:E19, 6:E24 Palop-Cubillo, L., 508 Renis, M., 98 Montini, G., 1048 Palumbo, M., 98 Rennke, H. G., 3:E11 Mora, C., 43 Pani, A., 618 Richart, C., 264 Morii, H., 832 Parekh, R., S1:1 Rigalleau, V., 500 Morita, A., 832 Parent, D., 486 Ritz, E., 150, 795 Moriya, H., 3:E10 Parsons, H. G., 669 Rivabella, L., 1048 Moroni, G., 530 Pasquali, Rocco, M. V., 721, 1075 Muda, A. O., 85 Passerini, P., 618 Rocha, J. L., 338 Passmore, J. C., 384 Rodriguez, M., 456 Mukoyama, M., 845 Mulgaonkar, S., 65 Patel, R. V., 222 Rodriguez-Carmona, A., 824 Murakami, R., 289 Patruta, S. 1., $2:25 Rodriguez-Puras, M. J., 338 Myerburg, R. J., 1105 Paueksakon, P., 768 Rohde, R., 818 Pauli-Magnus, C., 678 Rohde, R. D., 308 Paulson, W. D., 478 Rohdes, R. D., 809 Nadeau, J., 768 Peck, L. W., 324 Romeh, S. A., 55 Nagase, M., 611 Pegram, S., 254 Romero, R., 996 Nakabayashi, I., 3:E10 Pei, Y., 688 Roth, S., 150 Nakagawa, M., 845 Peixoto, A. J., 161 Rousset, H., 633 Nakamoto, H., 170 Pelletier, R. P., 731 Rovin, B. H., 761 Nakamura, H., 289, 854 Peralta, C., 264 Roys, E., S1:1 Nakanishi, K., 854 Pereira, B. J. G., 349 Rudolph, B., 556 1164 AUTHOR INDEX Ruml, L. A., 107 Shirakawa, T., 289, 854 Tesch, G. H., 761 Russo, A., 98 Shoji, T., 832 Thistlethwaite, J. R., 69, 540 Rychlik, I., 795 Short, R., 918 Thomas, M., 1033 Ryuzaki, M., 170 Shortland, J. R., 521 Thomas, S., 678, 1139 Shyr, Y., 471 Thompson, C. R., 125 Sibai-Galland, R., 839 To, K. F, 3:E12 Saad, T. F.,, 1114 Silbiger, S., 884 Tobe, S., 125 Saatci, U., 140 Simpson, P. M., 207 Tokura, T., 114 Saavedra-Santana, P., 508 Sagnella, G. A., 583 Singer, J., 125 Tonolo, G., 1002 Singh, S., 560 Torra, R., 273 St. Pierre, D., 14 Sakai, O., 902 Sklar, A., 464 Torres, A., 43 Sakhuja, V., 6:E25 Smetana, S., 438 Torres, V. E., 6: xlv-xl viii Salinas-Madrigal, L., 92 Solini,A. , 1002 Touchette, M. A., 222 Saller, A., 1002 Sorkin, M. 1., 228 Townsend, R. R., 120 Sorof, J. M., 49 Toz, H., 218 Samsell, L. S., 228 Samuels, A., 5:E21 Soubrier, M., 633 Tracy, T. S., 228 Sanchez, P., 264 Soucie, J. M., 254 Traeger, J.. 839 Souweine, B., 633 Trendelenburg, M., 745 Sanchez-Guisande, D., 996 Spath, P. J., 745 Truong, L. D., 5:E22 Sardu, C., 1002 Sauron, C., 633 Spencer, C. E., 706 Tsiouris, N., 5:E21 Sawaya, D. E., 61 Spitalewitz, S., 308 Tsujimoto, Y., 832 Sawyer, R., 706 Stack, A., S1:1 Tuncbilek, E., 140 Scalamogna, M., 1048 Stahl, R. A. K., 5:E20 Turner, M. S., 694 Schaefer, J. P., 669 Stamm, E. R., 120 Turney, J. H., 36 Schifferli, J. E., 745 Stenvinkel, P., 947, 1083 Tuttle, K. R., 918 Stone, J. H., 1040 Schilird, G., 98 Schmid, M., 1146 Stone, S. M., 254 Ubara, Y., 926 Schmidt, K.-H., 150 Stopper, H., 433 Umpleby, S., 36 Schmidt, M., 569 Strain, J. D., 639, 4:E17 Ungkanont, A., 29 Schmidt, R. J., 228 Strawderman, R. L., S1:1 Unsal, I., 140 Schmidt-Nowara, W., 739 Strife, C. F., 1022 Unsal, A., 218 Schmitz, P. G., 92 Sud, K., 6:E25 Uribarri, J., 493 Schneider, B., 247 Sugahara, S., 170 Utsunomiya, Y., 902 Sugar, L., 3:E13 Schultz, J., 464 Sugawara, A., 845 Schulze, D. G., 324 Vamvakas, S., 433 Sugimori, H., 1096 Schwab, S. J., 362, 3:xxxviii Van Es, L. A., 344 Schwab, T. R., 549 Sumino, K., 854 Van Buren, D. H., 869 Scott, R., 464 Sunder-Plassmann, G., $2:25 Van der Woude, F. J., 364 Scott-Douglas, N. W., 669 Suzuki, H., 170 Van Melle, G., 2:E3 Scrivo, D., 445 Swaminathan, S., 6:E25 Vardinon, N., 146 Seigle, R. L., 184 Swartz, R. D., 424 Vega-Diaz, N., 508 Semenyuk, L., 464 Szezech, L.,.$2:5 Verburgh, C. A., 344 Sfriso, A., 1002 Szeto, C.-C., 235, 514, 3:E12, 1056, Viberti, GC., 1139 1132 Shapiro, J. I., 304 Vidiella, J., 264 Sharma, A. P., 646 Villa, M., 618 Sharma, K., 4:E16, 818 Tabata, T., 832 Volpini, R., 328 Sharma, R. K., 646 Tagami, T., 926 Vonesh, E. F., 713 Sharp, C. K., 863 Taguma, Y., 894 Vychytil, A., 247 Shaver, M. J., 942 Takemoto, F., 926 Shayakul, C., 374 Takemura, T., 1016 Waiser, J., 556, 3:E9 Shemin, D., 14 Tam, J. S., 1132 Wang, A. Y. M., 3:E12 Sherman, R. A., 972 Tanaka, I., 845 Wang, T., 1083 Sherrard, D. J., 688 Tanaka, K., 845 Wang, X.-Q., 706 Sheth, A., 5:E22 Tanaka, R., 289 Warnock, D. G., 579 Shickle, L. M., 694 Tanaka, S., 926 Wassermann, A., 445 Shih, D., 713 Tang, S., 380 Watkins, S. L., 651 Shimatsu, A., 845 Tanimu, D., 55 Weaver, C. M., 324 Shinn, C., 304 Taylor, C. A., TIT, 657 Webb, R. L., S1:1 Shinozaki, M., 279 Tedeschi, P. J., S1:1 Weber, J., 678 Shiozawa, S., 289 Terreros, D., 549 Wechsler, B., 633 SUBJECT INDEX Weir, M. R., 1 Wong, T. Y. H., 235, 514, 1056, 1132 Yokota, S., 228 Weisberg, L. S., 1010 Woodle, E. S., 69, 540 Yoshikawa, N., 289, 854 Weiss, N. S., 688 Woodrow, G., 3 Yoshioka, K., 1016 Werner, D., 2:E3 Work, J., 61, 478, 597 Young, E. W., S1:1 West, C. D., 1022 Wright, M. J., 36 Yu, A. W. Y., 1056 Wheeler, J. R., S1:1 Yusa, N., 894 Whittier, F., 308 Xia, H., 1065 Yust, I., 146 Williams, R. A., Jr., 549 Xu, H., 289 Wilmer, W. A., 308 Winchester, J. F., 1:xxxvi Yahata, K., 845 Zaltzman, J. S., 3:E13 Wisniewska, J., 663 Yamada, A., 926 Zamorani, E., 1048 Wit, E.-J. C., 69 Yamamoto, S., 1016 Zeligman, B. E., 863 Wolach, B., 1129 Yamamoto, T., 170 Zennaro, C., 1048 Wolf, B., 875 Yan, G., 493 Zhang, J.-Z., 189 Wolf, G., 5:E20 Yang, D.-H., 259 Zibari, G. B., 61 Wolfe, R. A., S1:1 Yip, P. S., 6:E26 Zimmerman, S. W., 657 Wong, 355 Yokota, M., 926 Ziyadeh, F. N., 818 Wong, R. W. S., 315 Yokota, N., 114 Zucchelli, P., 530 SUBJECT INDEX Articles under the rubric Of Nephrology and Nephrologists are referred to by journal number, a colon, and page numbers. Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number. Page references to Supplement | (August 1999) and Supplement 2 (October 1999) are preceded, respectively, by S1: and S82:. AAs (amino acids), reabsorption of, in pediatric FS second- Acidosis ary to chemotherapy, 100 glucocorticoids in, 960-965 Abbreviations, 1999 USRDS ADR, S1:7-8 and nutritional status of ESRD patients on HD, 493-499 ABD (aluminum-related bone disease), see Renal osteodys- ACKD (acquired cystic kidney disease) in ESRD children trophy in ESRD patients on HD on CAPD, 242-246 Abdominal pain, persistent, and prevalence of active CMV Acknowledgment for use of USRDS data, $1:35 in GI tract of RTx recipients, 65-68 Acquired cystic kidney disease (ACKD) in ESRD children ABO blood group, and RTx for ESRD, USRDS 1999 ADR on, $1:98 on CAPD, 242-246 Abstracts citing USRDS data, $1:29 Actin, see Smooth muscle actin; a-Smooth muscle actin Abusive end-stage renal disease patients, see Physician’s Active cytomegalovirus (CMV) infection in GI tract of RTx duties to abusive, aggressive, or disruptive ESRD recipients, persistent abdominal pain, 65-68 patients on HD Acute c-anti-neutrophil cytoplasmic-positive vasculitis, MMF Acceptance into ESRD therapy, $1:162-164 for, 3:E9 Access, vascular, see Vascular access, HD Acute interstitial nephritis (AIN), 4:E14 Access to RTx, USRDS 1999 ADR on, S1:96-98 drug-induced renal allograft, histopathology and course executive summary of, S1:15-16 of, 540-548 by pediatric patients, S1:109-110 Acute rejection ACE, see: ACE gene; Angiotensin-converting enzyme; An- pulse methylprednisolone for, time course of response to, giotensin-converting enzyme inhibitor(s) 304-307 ACE gene racial disparities in, 709 in NIDDM siblings, MA and, 1002-1009 see also Polymorphism of ACE gene Acute renal failure (ARF) Acid/base homeostasis bedside renal biopsy for, 956 effects of Pi replacement for hypophosphatemia on, in CRRT of, see Acute renal failure, CRRT of RTx recipients, 875-883 due to immersion in seawater polluted by diesel oil, 6:E26 see also pH due to paradoxical embolism, 752-755 1166 SUBJECT INDEX neonatal, due to transplacental transfer of nephrotoxic Age paraprotein, exchange transfusion for, 1129-1131 of ADPKD patients with colonic diverticular disease, 865 renal AED with, gallium-67 uptake in, 161-165 of bedside renal biopsy patients, 956 with Rosai-Dorfman disease, 3:E12 of CAD patients, 920, 922 streptococcal toxic shock syndrome with desquamating of chronic GN patients, 115 erythema and, 150-154 of DM patients, see Age of DM patients see also Neutrophils in ARF of early renal disease patients, LVH and, 127, 129, 131 Acute renal failure (ARF), CRRT of of ESRD patients, see Age of ESRD patients on RRT convective clearances with, at various dialysate and ultra- of FS patients, 99 filtration flow rates, 486-492 of FSGS patients, 620 see also Diffusive clearances, and CRRT of ARF of HTN patients, see Age of HTN patients Acute tubular necrosis (ATN) of hypokalemic patients, 109 in diabetes mellitus, HD for, 1010-1015 of IgAN patients, see Age of IgAN patients spontaneous graft rupture due to, 355-358 of IMN patients, 523 Acute vision loss with pediatric ARPKD, 1125-1128 of LN patients, 317, 319 Acylcarnitine, serum, L-carnitine effects on, 682, 685 of MGN and LMGN patients, 86 Address of USRDS site on World Wide Web, $1:25 of MPGN patients, 1024 Adenosine triphosphatase (ATPase) in pediatric FS second- of nephrotic-range proteinuria patients, 136, 137 ary to chemotherapy, 101 of NS patients, 612 Adequacy of dialysis of POEMS syndrome patients, 634 of CAPD, independent effects of RRF and, on nutritional of proliferative GN patients, DSG effects and, 895 status of CAPD patients, 1056-1064 of recurrent Goodpasture’s syndrome, 554 on prolonged slow HD, 599-601 of severe ARF patients, 426, 428, 429 of TINU syndrome patients, 1017 quality improvement of, ESRD Core Indicators Project Age of DM patients report on, 1075-1082 with ATN, 1012 see also entries beginning with: Kt/V and reduced orthostatic cerebral blood flow due to HD, ADH (antidiuretic hormone), secretion of, and etiology of 1097 IE, 413 Adhesion molecules, role of, in neutrophil-induced renal see also Age of IDDM patients with HTN, captopril and; Age of NIDDM patients injury in ARF, 391-393 Age of ESRD patients, USRDS 1999 ADR on Adjusted death rates of ESRD patients, USRDS 1999 ADR adjusted first-year death rates by, $1:78 on, $1:75-77, $1:81-82, $1:153-154 causes of mortality by, $1:88-89, $1:91-93 annual, $1:166-171 expected remaining years of life by, $1:84-85, S1:173 first-year, S1:74-80 incidence and prevalence of treated ESRD by, S1:11, Adjustment $1:42-45, $1:47-49 standard population for, in USRDS 1999 ADR, 1:153 Medicare expenditures by, $1:132-135 see also Adjustment, rate, in USRDS 1999 ADR of new ESRD patients, $1:64 Adjustment (standardization), rate, in USRDS 1999 ADR, patient survival by, $1:172-173 $1:10, $1:152, $1:164-166 of pediatric patients, $1:102-107 see also Adjusted death rates of ESRD patients, USRDS RRT modality by, S1:57 1999 ADR on Age of ESRD patients with ADPKD on HD Admissions, see Hospitalization ACE gene polymorphism and, 275 ADPKD, see Autosomal dominant polycystic kidney disease valvular heart disease and, 266 ADR (Annual Data Report) of USRDS, see United States Age of ESRD patients on HD Renal Data System, 1998 ADR of; United States and association between acidosis and nutritional status, Renal Data System, 1999 ADR of 494, 496 Adrenomedullin (AM), plasma and urinary PAMP and, in with asymptomatic Al-related renal osteodystrophy, 690 chronic GN, 114-119 atherosclerotic vascular disease and, 671, 674 Adverse effects and CVD, 440 of parenteral Fe therapy, $2:44 effects of calcitriol and, on recovery from hypocalcemia, see also Adverse effects of immunosuppression 456-463 Adverse effects of immunosuppression Fe deficiency diagnosis and, 510 for LN, 525 gentamicin pharmacokinetics and, 223 of prolonged immunosuppression for FSGS, 623 hyperleptinemic, 825, 827 Adynamic bone disease, serum Mg and PTH levels in ESRD leukocyte phagocytic function and viability and, 681 patients on HD and, 43-48 on long-term maintenance HD, genomic damage to lym- AED (atheroembolic disease), renal, with ARF, gallium-67 phocytes and, 434, 435 uptake in, 161-165 new patients, serum Cr levels and, 696-698 African Americans, see Race race and, and outcome of HD, 723, 728 AFS (Annual Facility Survey), $1:157, $1:159 and relationship between serum Mg and PTH, 44, 45 SUBJECT INDEX 1167 rHuEPO and, 24, 1091 Aggressive end-stage renal disease patients, see Physician’s SAEG and, 1107 duties to abusive, aggressive, or disruptive ESRD serial VABF and, 472 patients on HD see also Age of ESRD patients with ADPKD on HD Aging-related glomerulosclerosis (GS), sex and, 884-888 Age of ESRD patients on PD/CAPD AGN gene in NIDDM siblings, MA and, 1002-1009 with asymptomatic Al-related renal osteodystrophy, 690 Agreement for data release, $1:38-39 Cr generation and, 236 AIN, see Acute interstitial nephritis and effects of aminoglycosides on RRF, 16, 17 Al, see Aluminum in ESRD patients on HD of new patients, SCr levels and, 696-698 Albumin NIDDM and, 516, 517 in LN, 536 nutritional status and, 1058 see also Albumin in ESRD patients; Microalbuminuria; PET measurement of D/P ratio and, 248 Plasma albumin; Proteinuria race and, see Age of ESRD patients on PD/CAPD, race Albumin in ESRD patients and serum, in RRT patients, see Serum albumin in ESRD see also Age of ESRD patients on PD/CAPD, Fe in; Age patients on RRT VLPD and, 501 of ESRD patients on PD/CAPD and IP rHuEPO therapy see also Albumin in ESRD patients on HD; Albumin in Age of ESRD patients on PD/CAPD, Fe in ESRD patients on PD/CAPD; Prealbumin in ESRD Fe deficiency diagnosis, 510 Albumin in ESRD patients on HD Fe status, 31 L-carnitine effects on, 683 Age of ESRD patients on PD/CAPD, leptin and CVD and, 440 hyperleptinemia, 825, 827 Fe deficiency and, 510 and leptin in dialysate, 833 and hyperleptinemia, 826, 827 in new ESRD patients, 696-698 and peritoneal leptin clearance, 840 Age of ESRD patients on PD/CAPD, race and Radix angelicae sinensis effects on, 350 see also Serum albumin in ESRD patients on HD familial aggregation of ESRD in HIVAN and, 248 and survival, 714, 716 Albumin in ESRD patients on PD/CAPD Fe deficiency and, 510 Age of ESRD patients on PD/CAPD and IP rHuEPO therapy and hyperleptinemia, 826, 827 “dry well” dosing technique and, 659 in new ESRD patients, 696-698 pediatric patients on CCPD, 654 race, survival and, 716 Age of ESRD patients on RRT Aldosterone, see Plasma aldosterone; Renin-aldosterone axis serum hyaluronan, survival and, 1084, 1085 Alkaline phosphatase (ALP) in ESRD patients on HD see also Age of ESRD patients on HD; Age of ESRD with ADPKD, 266 patients on PD/CAPD; Age of RTx recipients or CAPD, asymptomatic Al-related renal osteodystrophy Age of HTN patients and, 690 low-renin HTN patients, 581, 584 relationship between serum Mg and PTH and, 44, 45 with MA, 997 Allergic interstitial nephritis (IN), differentiation between see also Age of IDDM patients with HTN, captopril and renal AED and, with gallium-67 scan, 161-165 Age of IDDM patients with HTN, captopril and ALP, see Alkaline phosphatase in ESRD patients on HD captopril effects on IDDM course, 811 Alpha (a)-smooth muscle actin (a-SMA), expression of long-term renoprotection with captopril, 820 mesangial cell, and IgAN progression, 902-910 and NS remission with captopril, 310 Alport’s syndrome, X-linked, RT-PCR and direct sequenc- Age of IgAN patients, 906 ing in detection of COL4A5 gene mutations in, 854- with PAF-AH gene mutation, 292 862 with TCR Ca gene polymorphism, 282 Alternate-day prednisone, differences between types I and Age of NIDDM patients III MPGN in response to, 1022-1032 on CAPD, 516, 517 Aluminum (Al) in ESRD patients on HD with MA, ACE and AGN genes and, 1004 plasma, asymptomatic ABD and, 688-693 Age of RTx recipients and resistance to rHuEPO, 350, 352 with CMV infection, persistent abdominal pain and, 66 serum, and relationship between serum Mg and PTH, de novo FSGS in renal graft and, 733-735 44, 45 and drug-induced renal graft AIN, 542 see also Renal osteodystrophy in ESRD patients on HD for FSGS, 1049 AM (adrenomedullin), plasma and urinary PAMP and, in hypophosphatemic, 876 chronic GN, 114-119 oral CsA versus SGC formulation and, 871 Amino acids (AAs), reabsorption of, in pediatric FS second- parvovirus B19 infection and PRCA and, 1134, 1135 ary to chemotherapy, 100 quality of life and, 62 Aminoglycosides, effects of, on RRF of PD patients, 14-20 race, RTx outcome and, 708 Amyloidosis Aggregation size, minimum, in USRDS 1999 ADR analyti- de novo augloid light chain, benign monoclonal gammopa- cal methods, $1:154 thy turning into, after RTx, 166-169 1168 SUBJECT INDEX idiopathic myelofibrosis complicated by, 6:E27 Annual renal transplantation (RT; RTx) for ESRD, USRDS systemic, as primary diagnosis, 138 1999 ADR on, 166-171 Analgesic nephropathy, as primary disease, 435 ANP (atrial natriuretic peptide), proadrenomedullin N- Analysis files, USRDS terminal 20 as, plasma and urinary AM and, in for researchers, $1:26-35 chronic GN, 114-119 see also specific analysis files Anterior ischemic optic neuropathy, and acute vision loss in pediatric ARPKD, 1125-1128 Analytical methods used in USRDS 1999 ADR, S1:18-19, Antibody(ies) $1:152-176 for annual mortality, hospitalization, and RTx, $1:166-171 aPL antibody syndrome in RTx for ESRD secondary to SLE, 1040-1047 database and, see Database, USRDS monoclonal IgA-« circulating, recurrent Goodpasture’s to determine causes of mortality, $1:87-88, S1:153 syndrome due to, 549-555, 565-568 for expected remaining years of life, $1:173 Anti-Clq autoantibodies in HUVS and SLE, 745-751 for graft survival, $1:152, $1:173 Antidiuretic hormone (ADH), secretion of, and etiology of intent-to-treat model in, $1:174-176 IE, 413 lost-to-follow-up classification methods in, $1:160-162 Antigens, see HLA measurement concepts in, $1:162-164 Anti-glomerular basement membrane (GBM) antibody dis- for Medicare claims, $1:174 ease, recurrent Goodpasture’s syndrome due to mono- for patient survival, $1:152, $1:171-173 clonal IgA-« circulating antibody and, 549-555, 565- for rate adjustment, see Adjustment, rate, in USRDS 1999 568 ADR Anti-glomerular basement membrane (GBM) nephritis, for treatment modalities, $1:173-174 ANCA-associated pauci-immune GN and, 344-348 what’s new in, $1:152-154 Antihypertensive drugs PANCAs, see Anti-neutrophil cytoplasmic autoanti- effects of, on MA in hypertension, 984-985 body(ies); c-Anti-neutrophil cytoplasmic autoanti- see also specific classes of antihypertensives; for ex- body-positive vasculitis ample: Angiotensin-converting enzyme inhibitor(s) Anemia Anti-neutrophil cytoplasmic autoantibody (ies) (ANCA), anti- of ESRD, see Iron deficiency in ESRD patients on HD; glomerular basement membrane nephritis and pauci- Iron deficiency in ESRD patients on PD/CAPD; immune GN associated with, 344-348 Recombinant human erythropoietin for anemic ESRD c-Anti-neutrophil cytoplasmic autoantibody (ANCA)- patients positive vasculitis, acute, MMF for, 3:E9 and LVH in early renal disease, 125-134 Antioxidants, level of, in ESRD patients on HD treated or in pediatric ARPKD, acute vision loss and, 1125-1128 not treated with enalapril, 445-455 ANF (atrial natriuretic factor), levels of, and etiology of IE, Antiphospholipid (aPL) antibody syndrome in RTx for ESRD 413-414 secondary to SLE, 1040-1047 Angina in ESRD patients on HD, L-carnitine effects on, 683 Anti-tubular basement membrane (anti-TBM) nephritis, dif- Angioaccess, HD, see Vascular access, HD ferentiating between partial pediatric FS and, 184-188 Angiography, coronary, in detection of CAD, 918-925 Aortic bacterial endocarditis due § haemolyticus catheter infection, inverse paradoxical embolism with, in Angiotensin-converting enzyme (ACE) chronic HD patient, 338-340, 362-363 activity of serum, in NIDDM ESRD patients on CAPD, APD, see Automated peritoneal dialysis for ESRD 514-520 aPL (antiphospholipid) antibody syndrome in RTx for ESRD see also: ACE gene; Angiotensin-converting enzyme in- secondary to SLE, 1040-1047 hibitor(s) Aplasia, pure red cell, parvovirus B19 infection causing, in Angiotensin-converting enzyme (ACE) inhibitor(s) RTx recipients on tacrolimus, 1132-1136 captopril as, see Captopril Apnea, sleep, effects of rHuEPO for HD patients on HD, effects of, on progression of renal disease, 626-632 1089-1095 enalapril as, antioxidant defense level in ESRD patients Apnea hypoapnea syndrome, reversal of sleep, following on HD treated or not treated with, 445-455 RTx for ESRD, 739-744 in NIDDM ESRD, 802 Apolipoprotein A (apo-A) in ESRD patients on HD, CVD PD patients on, RRF and, 16, 17 and, 440, 441 proteinuria and, see Proteinuria, ACE inhibition and Apolipoprotein B (apo-B) in ESRD patients on HD, CVD Anion gap, and SAHS in RTx recipients, 741 and, 440, 441 Annual adjusted death rate of ESRD patients, USRDS 1999 ARF, see Acute renal failure ADR on, $1:166-171 Arginine on HD, indices of activity of, 228-234 Annual Data Report of USRDS, see United States Renal ARPKD (autosomal recessive polycystic kidney disease), Data System, 1998 ADR of; United States Renal Data pediatric, acute vision loss in, 1125-1128 System, 1999 ADR of Arterial embolization, transcatheter renal, in ADPKD pa- Annual Facility Survey (AFS), $1:157, $1:159 tients with ESRD on HD, 926-931 Annual hospitalization for ESRD, USRDS 1999 ADR on, Arterial pressure, see Blood pressure $1:166-171 Arteriolar dilation in IE, 408 SUBJECT INDEX 1169 Arteritis, see Polyarteritis nodosa Azathioprine, effects of prednisolone and, on progression of Asia, incidence and prevalence of treated NIDDM ESRD in, IMN, 521-529 800-801 Azide, tissue exposure to, and glucose transport regulation Asian Americans, see Race by hypoxia, 189-202 Aspirin, effects of, on heparin requirements of ESRD pa- tients on HD, 38 Bacteremia associated with tunneled, cuffed, permanent HD Assessment of abusive and/or aggressive patients and their catheters, 1114-1124 noncompliance, 781-782 Bacterial endocarditis, aortic, due S$ haemolyticus catheter Asymmetry, renal, in children with ADPKD, 639-645, 4:E17 infection, inverse paradoxical embolism with, in Asymptomatic aluminum-related bone disease (ABD) in chronic HD patient, 338-340, 362-363 ESRD patients on HD or CAPD, 688-693 Bacterial virulence, Fe effects on, $2:48-49 AT] receptor gene, and scarring in VUR, 140-145 Bartter’s syndrome, Gitelman’s syndrome as subtype of, ATG gene, and scarring in VUR, 140-145 R642C missense mutation of TSC gene in, 845-853 Atheroembolic disease (AED), renal, with ARF, gallium-67 BD (bullous dermatoses) in ESRD patients on CAPD, uptake in, 161-165 155-160 Atherosclerosis, MA in TNH and, 996-1001 Bedside renal biopsy, ultrasound guidance for, 955-959 Atherosclerotic vascular disease, hyperhomocyst(e)nemia Benign monoclonal gammopathy turning to de novo augloid and prevalence of, in ESRD patients on HD, 669-677 light chain amyloidosis after RTx, 166-169 Berger’s disease, see IgA nephropathy Atlas of renal pathology, 1:E1, 2:El, 3:E7, 4:E14, 5:E18, 6:E23 Beta (8) cells, function of, in NIDDM patients on CAPD for ESRD, homeostasis model analysis of, 514-520 ATN, see Acute tubular necrosis ATPase (adenosine triphosphatase) in pediatric FS second- Beta,-microglobulin, see B.-Microglobulin ary to chemotherapy, 101 BF (blood flow), see Vascular access blood flow, HD Atrial natriuretic factor (ANF), levels of, and etiology of IE, Bicarbonate, see NaHCO, 413-414 Bilateral hydronephrosis without obstruction, reversibility of, in HBV infection-associated PAN, 3:E11 Atrial natriuretic peptide (ANP), proadrenomedullin N- Bilateral renal infarction secondary to paradoxical embo- terminal 20 as, plasma and urinary AM and, in lism, 752-755 chronic GN, 114-119 Bilirubin, total, in severe ARF, 427-430 Augloid light chain amyloidosis, de novo, benign monoclo- Bioavailability of oral CsA versus SGC formulation, 869-874 nal gammopathy turning into, after RTx, 166-169 Biochemistry Autoantibodies of NIDDM patients on CAPD for ESRD, relationship anti-Clq, in HUVS and SLE, 745-751 between insulin requirements and, 514-520 see also Anti-neutrophil cytoplasmic autoantibody(ies); see also specific biochemical data c-Anti-neutrophil cytoplasmic autoantibody-positive Biocompatible membranes, see High-flux biocompatible vasculitis membranes, HD for ESRD with Automated literature search in online features of AJKD, Biological marker of Fe status, see Serum ferritin 1137-1138 Biomedical Scientific Advisory Committee (B-SAC), Automated peritoneal dialysis (APD) for ESRD USRDS, S1:5 aminoglycosides and RRF on, 17 Biopsy influence of preceding exchange on PET results on, bone, of renal osteodystrophy, 4:1x 247-253 see also Histopathology; Renal biopsy Automated spring-loaded gun device, percutaneous renal Black Americans, see Race biopsy using ultrasound-guided, effects of, on bleed- Bleeding due to percutaneous renal biopsy, effects of using ing, and implications for early hospital discharge, ultrasound-guided automated spring-loaded gun de- 92-97 vice on, 92-97 Autosomal dominant polycystic kidney disease (ADPKD) Blood flow without ESRD, colonic diverticular disease with, 863-868 velocity of orthostatic cerebral, HD for diabetes mellitus extrarenal manifestations of, 6: xlv-xlviii and reduction of, 1096-1104 see also Autosomal dominant polycystic kidney disease, see also Vascular access blood flow, HD ESRD patients on HD with; Cyst(s) in ADPKD Blood group, ABO, and RTx for ESRD, USRDS 1999 ADR Autosomal dominant polycystic kidney disease (ADPKD), on, $1:98 ESRD patients on HD with, 264-278 Blood pressure (BP) ACE gene polymorphism and progression of renal failure in, in chronic GN, 115 273-278 in doxorubicin-induced nephropathy, NaHCO; effects on, echocardiography of cardiac complications in, 264-272 331, 334 transcatheter renal arterial embolization in, 926-931 in ESRD patients on CAPD, NIDDM and, 516, 517, 802; Autosomal recessive polycystic kidney disease (ARPKD), see also Blood pressure of ESRD patients on HD pediatric, acute vision loss in, 1125-1128 in Gitelman’s syndrome, 846 Availability of kidneys, RTx and, USRDS 1999 ADR on, in IE, 416 $1:95-96 in IgAN, 282, 906 1170 SUBJECT INDEX in IMN, 523 Body weight (BW) of DM patients in MGN and LMGN, 86 on HD, and orthostatic hypotension and, 1100 in proliferative GN, DSG effects on, 895 and remission of NS with captopril in IDDM, 310 and remission of NS with captopril in IDDM, 310 Body weight (BW) of ESRD patients on HD in severe ARF, 427-430 acidosis, nutritional status and, 496 see also Hypertension; Hypotension and Fe status, 31 Blood pressure (BP) of ESRD patients on HD gentamicin pharmacokinetics and, 223 with ADPKD, valvular heart disease and, 266 and HTN, 220 and CVD, 440, 441 race and, and HD outcome, 728 intradialytic serial VABF and, 471-477 SAECG and, 1108 in NIDDM ESRD, 802 Body weight (BW) of ESRD patients on PD/CAPD on prolonged slow HD, 602-603 Cr generation and, 236 SAECG and, 1108 effects of aminoglycosides on RRF and, 16, 17 venous, of HD access grafts, monitoring of, at high blood and IP rHuEPO administration, 659 flow, and graft failure prediction, 212-217 NIDDM and, 516, 517 Blood urea nitrogen, see BUN nutritional status and, 1058 BMI, see Body mass index race, survival and, 715 Body composition of ESRD patients on VLPD, DEXA in Bone disease, see Renal osteodystrophy in ESRD patients assessment of outcome of, 500-507 on HD Body fat, total, in ESRD patients, VLPD and, 501, 503-504 Bone marrow of ESRD patients on CAPD, Fe content of, Body mass index (BMI) 29-35 of CAD patients, 920 BP, see Blood pressure of ESRD patients, see Body mass index of ESRD patients Breast cancer, scleroderma renal crisis and sclerosis associ- of HTN patients, see Body mass index of HTN patients ated with, 937-941 of NIDDM patients with MA, ACE and AGN genes and, Bromocriptine in IE, 416 1004 B-SAC (Biomedical Scientific Advisory Committee), Body mass index (BMI) of ESRD patients USRDS, S1:5 on RRT, serum hyaluronan and survival and, 1084; see Bullous dermatoses (BD) in ESRD patients on CAPD, also Body mass index of ESRD patients on HD; 155-160 Body mass index of ESRD patients on PD/CAPD BUN (blood urea nitrogen) VLPD and, 501 and bleeding due to percutaneous renal biopsy, 93 Body mass index (BMI) of ESRD patients on HD in DM patients on HD, orthostatic hypotension and, 1100 acidosis, nutritional status and, 495, 496 in MGN and LMGN, 86 cardiac complications in patients with ADPKD, 266 in nephrotic-range proteinuria, 136, 137 and hyperleptinemia, 826, 827 in proliferative GN, DSG effects on, 895 of new ESRD patients, 696-698 and RTx, 741 Body mass index (BMI) of ESRD patients on PD/CAPD in severe ARF, 427-430 Cr generation and, 236 see also BUN in ESRD patients on HD; BUN in ESRD of new ESRD patients, 696-698 patients on PD/CAPD nutritional status and, 1058 BUN (blood urea nitrogen) in ESRD patients on HD see also Body mass index of ESRD patients on PD/ acidosis, nutritional status and, 495, 496 CAPD, leptin and gentamicin pharmacokinetics and, 223 Body mass index (BMI) of ESRD patients on PD/CAPD, in new ESRD patients, 696-698 leptin and in pediatric ESRD patients, 53 with hyperleptinemia, 826-828 BUN (blood urea nitrogen) in ESRD patients on PD/CAPD and leptin in dialysate, 833, 834 in new ESRD patients, 696-698 and peritoneal leptin clearance, 840 race, survival and, 715 Body mass index (BMI) of HTN patients BW, see Body weight with low-renin HTN, 581-584 with MA, 997 C difficile (Clostridium difficile), IgAN associated with, Body temperature in severe ARF, 427-430 4:E16 Body weight (BW) Clq (complement Iq), autoantibodies against, in HUVS and of DM patients, see Body weight of DM patients SLE, 745-751 of ESRD patients, VLPD and, 501; see also Body weight C3 (complement 3) of ESRD patients on HD; Body weight of ESRD serum, in LN, 317 patients on PD/CAPD in types I and III MPGN, 1022-1032 of hypokalemic patients, 109 C4 (complement 4), serum, in LN, 317 of hypophosphatemic RTx recipients, 876 Ca (calcium) of IE patients, morning-evening differences in, 416 in DM patients on HD, and orthostatic hypotension, 1100 of renal insufficiency patients, LVH and, 127, 129, 131 in nephrotic-range proteinuria, 136, 137 of severe ARF patients, 427-430 in recurrent Goodpasture’s syndrome, 551

See more

The list of books you might like

Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.